Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Vision Disturbances in Multiple Sclerosis.
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection.
Dimethyl fumarate regulates histone deacetylase expression in astrocytes.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
WT1 and interferon-β-vitamin D association in MS: a longitudinal study.
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
Mechanism of action for leflunomide in rheumatoid arthritis.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.

Pages